News from mirati therapeutics, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

( NASDAQ-SMALL:MRTX)

Jan 08, 2016, 08:15 ET

Mirati Therapeutics Appoints Marcy Graham Vice President, Investor Relations and Corporate Communications

Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that Marcy Graham has been appointed Vice President, Investor Relations (IR) and Corporate...

Dec 21, 2015, 08:16 ET

Guardant Health And Mirati Therapeutics Enter Into Collaboration On Glesatinib (MGCD265) In Non Small Cell Lung Cancer (NSCLC) Trial

 Guardant Health, the market leader in liquid biopsies, and Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX), a targeted oncology company...

Dec 21, 2015, 08:16 ET

Foundation Medicine And Mirati Therapeutics Collaborate To Develop A Companion Diagnostic For Glesatinib (MGCD265) In Non-Small Cell Lung Cancer (NSCLC)

 Foundation Medicine, Inc. (NASDAQ: FMI) and Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX), a targeted oncology company focusing on...

Dec 21, 2015, 08:15 ET

Mirati Therapeutics Initiates Glesatinib (MGCD265) Phase 2 Trial In Non-Small Cell Lung Cancer (NSCLC)

 Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the Phase 2 clinical trial of glesatinib (MGCD265) has commenced. The Company...

Dec 17, 2015, 08:15 ET

Mirati Therapeutics Doses First Patient In Expansion Cohorts Of MGCD516 Phase 1b Trial In Genetically Selected Patients

 Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the first patient with Non-Small Cell Lung Cancer (NSCLC) has been dosed in a...

Dec 01, 2015, 08:15 ET

Mirati Therapeutics To Present At The Oppenheimer 26th Annual Healthcare Conference

 Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) will be presenting at the Oppenheimer 26th Annual Healthcare Conference on Tuesday,...

Nov 06, 2015, 08:15 ET

Mirati Therapeutics Reports Third Quarter 2015 Financial Results And Provides Business Update

 Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today reported financial results for the third quarter ended September 30, 2015 and...

Sep 28, 2015, 08:00 ET

Mirati Therapeutics Presents Interim Clinical Data From Ongoing MGCD516 Phase 1 Dose Escalation Study In Patients With Advanced Solid Tumors

 Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX), an oncology company focusing on genetic and epigenetic drivers of cancer, today announced...

Sep 15, 2015, 20:35 ET

Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock

 Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the pricing of an underwritten public offering of 2,250,000 shares of its common...

Sep 14, 2015, 16:01 ET

Mirati Therapeutics Announces Proposed Public Offering of $80 Million of Common Stock

 Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that it intends to offer and sell, subject to market and other conditions,...

Sep 11, 2015, 08:00 ET

Mirati Therapeutics To Present Clinical Data At The European Society for Medical Oncology (ESMO) 2015 European Cancer Congress

Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX), an oncology company focusing on genetic and epigenetic drivers of cancer, today announced it...

Sep 09, 2015, 08:00 ET

MGCD265 DEMONSTRATES CLINICAL EFFICACY WITH CONFIRMED RESPONSES IN NSCLC PATIENTS WITH MET AND AXL GENE AMPLIFICATION

Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX), an oncology company focusing on genetic and epigenetic drivers of cancer, today announced it...

Aug 21, 2015, 19:05 ET

Mirati Therapeutics To Present Preclinical And Clinical Data At The IASLC 16th World Conference On Lung Cancer

 Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX), an oncology company focusing on genetic and epigenetic drivers of cancer, today announced...

Aug 06, 2015, 16:01 ET

Mirati Therapeutics Reports Second Quarter 2015 Financial Results and Provides Business Update

 Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today reported financial results for the second quarter ended June 30, 2015 and provided...

Aug 05, 2015, 07:00 ET

Mirati Therapeutics And MedImmune Partner On Immuno-Oncology Combination In Lung Cancer

 Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX), an oncology company focusing on genetic and epigenetic drivers of cancer, and MedImmune,...

Aug 04, 2015, 08:00 ET

Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference

 Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX),  a targeted oncology company focusing on genetic and epigenetic drivers of cancer,...

May 30, 2015, 09:16 ET

Initial Data from Ongoing Expansion Study of MGCD265 Show Preliminary Evidence of Clinical Efficacy in Heavily Pretreated Non-Small Cell Lung Cancer (NSCLC) Patients with MET Gene Alterations

 Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today presented data that demonstrated preliminary evidence of clinical activity from its...

May 27, 2015, 08:00 ET

Mirati Therapeutics To Present At The Jefferies 2015 Global Healthcare Conference

Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) will be presenting at the Jefferies 2015 Global Healthcare Conference on Wednesday, June 3 at...

May 13, 2015, 17:05 ET

Mirati Therapeutics to Provide Updates on Pipeline Programs at 2015 ASCO Annual Meeting

 Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today announced that the Company will provide an update on its investigational targeted...

May 06, 2015, 16:01 ET

Mirati Therapeutics Reports First Quarter 2015 Financial Results and Provides Business Update

 Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today reported financial results for the first quarter ended March 31, 2015 and provided...